{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:47:52Z","timestamp":1788997672507,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd004136.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000}}],"reference-count":168,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004136.pub3","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T18:53:45Z","timestamp":1354820025000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antihypertensive agents for preventing diabetic kidney disease"],"prefix":"10.1002","volume":"2013","author":[{"given":"Jicheng","family":"Lv","sequence":"first","affiliation":[{"name":"The George Institute for Global Health; Renal and Metabolic Division; Level 10, KGV Building, RPAH Missenden Rd Camperdown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health; Renal and Metabolic Division; Level 10, KGV Building, RPAH Missenden Rd Camperdown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine V","family":"Foote","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health; Renal and Metabolic Division; Level 10, KGV Building, RPAH Missenden Rd Camperdown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Craig","sequence":"additional","affiliation":[{"name":"University of New South Wales; Divison of Women's and Children's Health; St George Hospital Gray Street Kogarah NSW Australia 2025"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100"},{"name":"Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"},{"name":"Diaverum; Medical-Scientific Office; Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD004136.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.amjhyper.2006.05.011","article-title":"Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes","volume":"19","author":"Estacio","year":"2006","journal-title":"American Journal of Hypertension"},{"issue":"Oct","key":"10.1002\/14651858.CD004136.pub3-BIB0002|cit2","first-page":"568A","article-title":"Aggressive blood pressure control with valsartan in normotensive Type 2 diabetic patients results in regression of albuminuria. [abstract]","volume":"15","author":"Estacio","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004136.pub3-BIB0003|cit3","first-page":"114A","article-title":"Effects of a calcium channel antagonist versus an ace inhibitor on diabetic nephropathy [abstract]","volume":"9","author":"Estacio","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004136.pub3-BIB0004|cit4","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD004136.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004136.pub3-BIB0006|cit6","first-page":"146A","article-title":"Aggressive lowering of blood pressure in normotensive type 2 diabetic patients: beneficial effects on stroke, progression of retinopathy and nephropathy [abstract]","volume":"12","author":"Estacio","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0197-2456(95)00154-9","article-title":"Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial","volume":"17","author":"Estacio","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"9B","key":"10.1002\/14651858.CD004136.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"9R","DOI":"10.1016\/S0002-9149(98)00750-4","article-title":"Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial","volume":"82","author":"Estacio","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD004136.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2337\/diacare.19.11.1243","article-title":"Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM","volume":"19","author":"Savage","year":"1996","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD004136.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s001250050629","article-title":"Appropriate Blood Pressure Control in NIDDM (ABCD) Trial","volume":"39","author":"Schrier","year":"1996","journal-title":"Diabetologia"},{"issue":"9","key":"10.1002\/14651858.CD004136.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0026-0495(99)90121-X","article-title":"Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus","volume":"48","author":"Stabler","year":"1999","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"7","key":"10.1002\/14651858.CD004136.pub3-BIB0014|cit13","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1464-5491.2005.01596.x","article-title":"ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline","volume":"22","author":"ADVANCE Collaborative Group","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"24","key":"10.1002\/14651858.CD004136.pub3-BIB0013|cit14","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004136.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s001250100612","article-title":"Study rationale and design of ADVANCE: action in diabetics and vascular disease - preterax and diamicron MR controlled evaluation","volume":"44","author":"ADVANCE Management Committee","year":"2001","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0016|cit16","first-page":"S21","article-title":"Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation","volume":"19","author":"Anonymous","year":"2001","journal-title":"Journal of Hypertension - Supplement"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003495-200363991-00005","article-title":"ADVANCE Study: objectives, design and current status","volume":"63 Spec No. 1","author":"Chalmers","year":"2003","journal-title":"Drugs"},{"issue":"23","key":"10.1002\/14651858.CD004136.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1093\/eurheartj\/ehq139","article-title":"Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease","volume":"31","author":"Heerspink","year":"2010","journal-title":"European Heart Journal"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004136.pub3-BIB0019|cit19","first-page":"543A","article-title":"Predictive baseline factors for major renal events: a proportional hazards model based on the Advance Study [abstract]","volume":"19","author":"Jardine","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD004136.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/HJH.0b013e328338a89c","article-title":"Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial","volume":"28","author":"Ninomiya","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"9590","key":"10.1002\/14651858.CD004136.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0022|cit22","unstructured":"Perkovic V Ninomiya T de Galan BE Zoungas S Cass A Patel A Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB-002] American Society of Nephrology (ASN) Renal Week; 2008 Nov 4-9; Philadelphia, PA 2008"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004136.pub3-BIB0023|cit23","first-page":"42","article-title":"Intensive glucose lowering and end stage kidney disease - new data from the ADVANCE trial [abstract]","volume":"16","author":"Perkovic","year":"2011","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004136.pub3-BIB0024|cit24","first-page":"A121","article-title":"Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract]","volume":"13","author":"Perkovic","year":"2008","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000354417.70192.be","article-title":"Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE","volume":"27","author":"Poulter","year":"2009","journal-title":"Journal of Hypertension - Supplement"},{"issue":"11","key":"10.1002\/14651858.CD004136.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.2337\/dc09-0959","article-title":"Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial","volume":"32","author":"Zoungas","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004136.pub3-BIB0027|cit27","first-page":"A218","article-title":"Renoprotective effects of blood pressure lowering with perindopril-indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]","volume":"57","author":"Galan","year":"2008","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1681\/ASN.2008070667","article-title":"Lowering blood pressure reduces renal events in type 2 diabetes","volume":"20","author":"Galan","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","article-title":"Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics","volume":"54","author":"Baba","year":"2001","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0197-2456(03)00028-X","article-title":"The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics","volume":"24","author":"BENEDICT","year":"2003","journal-title":"Controlled Clinical Trials"},{"issue":"12","key":"10.1002\/14651858.CD004136.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.2337\/db09-0407","article-title":"Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT","volume":"58","author":"Cosmo","year":"2009","journal-title":"Diabetes"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD004136.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1681\/ASN.2005121324","article-title":"Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study","volume":"17","author":"Remuzzi","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/HJH.0b013e32834069bd","article-title":"Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial","volume":"29","author":"Ruggenenti","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"19","key":"10.1002\/14651858.CD004136.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004136.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2337\/dc08-0371","article-title":"Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)","volume":"31","author":"Ruggenenti","year":"2008","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD004136.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1681\/ASN.2006060560","article-title":"Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial","volume":"17","author":"Ruggenenti","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0037|cit37","first-page":"S95","article-title":"Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial","volume":"16","author":"Ruggenenti","year":"1998","journal-title":"Journal of Hypertension - Supplement"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3317\/jraas.2003.019","article-title":"Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design","volume":"4","author":"Andersen","year":"2003","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ajh.2007.2","article-title":"Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis","volume":"21","author":"Knudsen","year":"2008","journal-title":"American Journal of Hypertension"},{"issue":"6860","key":"10.1002\/14651858.CD004136.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/bmj.305.6860.981","article-title":"Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis","volume":"305","author":"Chan","year":"1992","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1523-1755.2000.00879.x","article-title":"Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients","volume":"57","author":"Chan","year":"2000","journal-title":"Kidney International"},{"issue":"7","key":"10.1002\/14651858.CD004136.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2337\/diacare.18.7.1001","article-title":"Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM","volume":"18","author":"Chan","year":"1995","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1002\/14651858.CD004136.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2337\/diacare.17.8.859","article-title":"The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM","volume":"17","author":"Chan","year":"1994","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00838494","article-title":"Hypertension and non-insulin-dependent diabetes","volume":"32","author":"Crepaldi","year":"1995","journal-title":"Acta Diabetologica"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"11-20, W3-4","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004136.pub3-BIB0047|cit47","article-title":"DIRECT-Renal: The effect of the angiotensive type 1 receptor blocker candesartan on the development of microalbuminuria in type 1 and type 2 diabetes [abstract]","author":"Bilous","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9647","key":"10.1002\/14651858.CD004136.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"9647","key":"10.1002\/14651858.CD004136.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"Sjolie","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"Sjolie","year":"2005","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"9095","key":"10.1002\/14651858.CD004136.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"issue":"9068","key":"10.1002\/14651858.CD004136.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group","volume":"349","author":"Chaturvedi","year":"1997","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD004136.pub3-BIB0054|cit54","first-page":"1357","article-title":"Renal effect of lisinopril in insulin dependent diabetes mellitus (IDDM) without hypertension [abstract]","volume":"7","author":"Fuller","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD004136.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2337\/diabetes.47.9.1507","article-title":"Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM","volume":"47","author":"Penno","year":"1998","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD004136.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1046\/j.1365-2362.2002.01011.x","article-title":"Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients","volume":"32","author":"Schalkwijk","year":"2002","journal-title":"European Journal of Clinical Investigation"},{"issue":"7","key":"10.1002\/14651858.CD004136.pub3-BIB0057|cit57","first-page":"949","article-title":"Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus","volume":"161","author":"Sjolie","year":"1999","journal-title":"Ugeskrift for Laeger"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti","year":"1998","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0059|cit59","first-page":"127","article-title":"The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators","volume":"12","author":"Anonymous","year":"1996","journal-title":"Canadian Journal of Cardiology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004136.pub3-BIB0062|cit60","first-page":"8","article-title":"Diabetes and the HOPE study: implications for macrovascular and microvascular disease","volume":"117","author":"Gerstein","year":"2001","journal-title":"International Journal of Clinical Practice"},{"issue":"11","key":"10.1002\/14651858.CD004136.pub3-BIB0060|cit61","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/diacare.19.11.1225","article-title":"Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation","volume":"19","author":"Gerstein","year":"1996","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD004136.pub3-BIB0061|cit62","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00125-005-1858-4","article-title":"The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis","volume":"48","author":"Gerstein","year":"2005","journal-title":"Diabetologia"},{"issue":"9200","key":"10.1002\/14651858.CD004136.pub3-BIB0063|cit63","first-page":"253","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"335","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3949\/ccjm.67.4.287","article-title":"The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not","volume":"67","author":"Hoogwerf","year":"2000","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004136.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.CIR.0000050600.49419.25","article-title":"Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study","volume":"107","author":"Lamy","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD004136.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.hjr.0000106836.977722.cf","article-title":"Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients","volume":"10","author":"Lonn","year":"2003","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"11","key":"10.1002\/14651858.CD004136.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2337\/diacare.25.11.1919","article-title":"Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy","volume":"25","author":"Lonn","year":"2002","journal-title":"Diabetes Care"},{"issue":"Sept","key":"10.1002\/14651858.CD004136.pub3-BIB0068|cit68","first-page":"156A","article-title":"Renal insufficiency (RI) as predicator of cardiovascular (CV) outcomes and impact of ramipril: the HOPE study [abstract]","volume":"11","author":"Mann","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD004136.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004136.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajkd.2003.07.015","article-title":"Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study","volume":"42","author":"Mann","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.ASN.0000051594.21922.99","article-title":"Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study","volume":"14","author":"Mann","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1523-1755.2004.00513.x","article-title":"Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study","volume":"65","author":"Mann","year":"2004","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CNP63181","article-title":"Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study","volume":"63","author":"Mann","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD004136.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","article-title":"Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril","volume":"104","author":"Mathew","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00365510500236366","article-title":"The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences","volume":"240","author":"McQueen","year":"2005","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation Supplement"},{"issue":"9299","key":"10.1002\/14651858.CD004136.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","article-title":"Blood-pressure reduction and cardiovascular risk in HOPE study","volume":"358","author":"Sleight","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.0000044940.65226.1F","article-title":"Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study","volume":"107","author":"Smieja","year":"2003","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD004136.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000038890.39298.8D","article-title":"Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events","volume":"106","author":"Veres","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Yusuf S Sleight P Pogue J Bosch J Davies R Dagenais G Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators New England Journal of Medicine 2000 145 53 10639539","DOI":"10.1056\/NEJM200001203420301"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0080|cit80","first-page":"52","article-title":"A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. Bombay Hypertension Study Group","volume":"Suppl 1","author":"Joglekar","year":"1998","journal-title":"Journal of the Association of Physicians of India"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-8227(02)00102-X","article-title":"The effects of losartan and fosinopril in hypertensive type 2 diabetic patients","volume":"58","author":"Kavgaci","year":"2002","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/qjmed\/94.2.89","article-title":"Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus","volume":"94","author":"Kvetny","year":"2001","journal-title":"Qjm"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0083|cit83","first-page":"30","article-title":"Beneficial effects of angiotensin-converting enzyme inhibitors on cardiovascular and renal functions in patients with hypertension and diabetes","volume":"11","author":"Lin","year":"1995","journal-title":"Acta Cardiologica Sinica"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: The ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.diabres.2008.12.005","article-title":"Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET\/TRANSCEND research programme","volume":"83","author":"Cukierman-Yaffe","year":"2009 Mar","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"9655","key":"10.1002\/14651858.CD004136.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)61860-7","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Gallieni","year":"2008","journal-title":"Lancet"},{"issue":"16","key":"10.1002\/14651858.CD004136.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/CIRCULATIONAHA.110.008870","article-title":"Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)","volume":"124","author":"Mancia","year":"2011","journal-title":"Circulation"},{"issue":"9638","key":"10.1002\/14651858.CD004136.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004136.pub3-BIB0089|cit89","first-page":"48A","article-title":"Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk: results from the ONTARGET trial [abstract]","volume":"17","author":"Mann","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004136.pub3-BIB0090|cit90","first-page":"48A","article-title":"Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk: results from the ONTARGET trial [abstract]","volume":"19","author":"Mann","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9655","key":"10.1002\/14651858.CD004136.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(08)61863-2","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Narayanan","year":"2008","journal-title":"Lancet"},{"issue":"9655","key":"10.1002\/14651858.CD004136.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)61861-9","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Nonoguchi","year":"2008","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD004136.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0094|cit94","first-page":"1","article-title":"Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme","volume":"3","author":"Ruilope","year":"2007","journal-title":"Vascular Health & Risk Management"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004136.pub3-BIB0095|cit95","first-page":"309A","article-title":"ONTARGET: cardiovascular outcome in patients at high cardiovascular risk and with chronic kidney disease (CKD) [abstract]","volume":"19","author":"Schmieder","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004136.pub3-BIB0097|cit96","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.hjh.0000357905.78704.9a","article-title":"Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor","volume":"27","author":"Sleight","year":"2009","journal-title":"Journal of Hypertension - Supplement"},{"issue":"7","key":"10.1002\/14651858.CD004136.pub3-BIB0096|cit97","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","article-title":"Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study","volume":"27","author":"Sleight","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","author":"Teo","year":"2004","journal-title":"American Heart Journal"},{"issue":"9655","key":"10.1002\/14651858.CD004136.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(08)61862-0","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Wetzels","year":"2008","journal-title":"Lancet"},{"issue":"Abstracts","key":"10.1002\/14651858.CD004136.pub3-BIB0100|cit100","first-page":"327A","article-title":"The effect of candesartan\/placebo treatment on renal function and morphology in diabetes type 1 [abstract]","volume":"18","author":"Perrin","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD004136.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00467-008-0745-x","article-title":"The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial","volume":"23","author":"Perrin","year":"2008","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0102|cit102","first-page":"559A","article-title":"Renal biopsy complications in the RASS study [abstract]","volume":"16","author":"Donnelly","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004136.pub3-BIB0103|cit103","first-page":"651A","article-title":"Effects of renin angiotensin system (RAS) blockade on diabetic nephropathy (DN)-a primary prevention trial: study design and baseline results [abstract]","volume":"13","author":"Donnelly","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD004136.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMc091561","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Katavetin","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0105|cit105","first-page":"554A","article-title":"The Renin Angiotensin System Study (RASS): compliance in a long-term kidney biopsy based diabetic nephropathy (DN) primary prevention trial in Type 1 diabetes mellitus (T1DM) patients (pts) [abstract]","volume":"16","author":"Mauer","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3317\/jraas.2002.048","article-title":"ACE-I and ARBs in early diabetic nephropathy","volume":"3","author":"Mauer","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004136.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.socscimed.2008.12.025","article-title":"Barriers to clinical research participation in a diabetes randomized clinical trial","volume":"68","author":"Robiner","year":"2009","journal-title":"Social Science & Medicine"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0109|cit109","unstructured":"Suissa S Renin angiotensin system study (RASS) of diabetic nephropathy (study protocol)"},{"issue":"14","key":"10.1002\/14651858.CD004136.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMc091561","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Tamsma","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"12 Pt 1","key":"10.1002\/14651858.CD004136.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","article-title":"Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial","volume":"128","author":"Ravid","year":"1998","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004136.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.hjh.0000202820.56201.e6","article-title":"Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study","volume":"24","author":"Haller","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0114|cit114","unstructured":"Haller HG Viberti GV Ritz E Ruilope LM Rabelink TJ for the ROADMAP Steering Committee Members Prevention of albuminuria and cardiovascular morbidity with olmesartan, the ROADMAP trial ASN Renal Week 2009 LB 005"},{"issue":"11","key":"10.1002\/14651858.CD004136.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/jhh.2010.111","article-title":"Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study)","volume":"25","author":"Januszewicz","year":"2011","journal-title":"Journal of Human Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/HJH.0b013e328351856d","article-title":"Prevention of microalbuminuria in patients with type 2 diabetes and hypertension","volume":"30","author":"Menne","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00125-009-1577-3","article-title":"Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study","volume":"53","author":"Ritz","year":"2010","journal-title":"Diabetologia"},{"issue":"8","key":"10.1002\/14651858.CD004136.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.2337\/diacare.20.8.1290","article-title":"Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients","volume":"20","author":"Scognamiglio","year":"1997","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: The ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004136.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.diabres.2008.12.005","article-title":"Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET\/TRANSCEND research programme","volume":"83","author":"Cukierman-Yaffe","year":"2009","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"11","key":"10.1002\/14651858.CD004136.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.106.661405","article-title":"Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk","volume":"115","author":"Held","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"9644","key":"10.1002\/14651858.CD004136.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Yusuf S. Teo K. Anderson C. Pogue J. Dyal L","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","author":"Teo","year":"2004","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD004136.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2337\/diacare.21.8.1345","article-title":"Long-term lisinopril therapy reduces exercise-induced albuminuria in normoalbuminuric normotensive IDDM patients","volume":"21","author":"Tuominen","year":"1998","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD004136.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/BF00400195","article-title":"UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance","volume":"34","author":"Anonymous","year":"1991","journal-title":"Diabetologia"},{"issue":"7160","key":"10.1002\/14651858.CD004136.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group","volume":"317","author":"Holman","year":"1998","journal-title":"BMJ"},{"issue":"9131","key":"10.1002\/14651858.CD004136.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UK PDS Group","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD004136.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","author":"UK PDS Group","year":"1998","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2337\/diab.45.2.216","article-title":"Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients","volume":"45","author":"Velussi","year":"1996","journal-title":"Diabetes"},{"issue":"23","key":"10.1002\/14651858.CD004136.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","journal-title":"JAMA"},{"issue":"9207","key":"10.1002\/14651858.CD004136.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(00)00092-1","article-title":"Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"355","author":"Messerli","year":"2000","journal-title":"Lancet"},{"issue":"9153","key":"10.1002\/14651858.CD004136.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"issue":"9192","key":"10.1002\/14651858.CD004136.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"issue":"9118","key":"10.1002\/14651858.CD004136.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"9227","key":"10.1002\/14651858.CD004136.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"issue":"9227","key":"10.1002\/14651858.CD004136.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD004136.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199903043400902","article-title":"Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators","volume":"340","author":"Tuomilehto","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004136.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","article-title":"Standards of Medical Care in Diabetes\u20142010","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD004136.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0142|cit142","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada Canadian Journal of Diabetes 2008 S1 S201"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1111\/j.1440-1797.2010.01240.x","article-title":"Prevention and management of chronic kidney disease in type 2 diabetes","volume":"15","author":"Chadban","year":"2010","journal-title":"Nephrology"},{"issue":"9647","key":"10.1002\/14651858.CD004136.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"issue":"19","key":"10.1002\/14651858.CD004136.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD004136.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","article-title":"2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension","volume":"25","author":"Mancia","year":"2007","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"6 Pt 2","key":"10.1002\/14651858.CD004136.pub3-BIB0148|cit148","first-page":"74","article-title":"Natural history of nephropathy in type I diabetes. Relationship to metabolic control and blood pressure","volume":"7","author":"Hasslacher","year":"1985","journal-title":"Hypertension"},{"issue":"7414","key":"10.1002\/14651858.CD004136.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0150|cit150","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0151|cit151","unstructured":"International Diabetes Federation IDF Diabetes Atlas http:\/\/www.idf.org\/diabetesatlas\/"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0152|cit152","unstructured":"American Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease http:\/\/www.kidney.org\/professionals\/KDOQI\/guideline_diabetes\/guide3.htm"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000133312.96477.48","article-title":"Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes","volume":"110","author":"Klausen","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ki.1992.128","article-title":"Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study","volume":"41","author":"Messent","year":"1992","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/00365517609055274","article-title":"Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment","volume":"36","author":"Mogensen","year":"1976","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"issue":"8","key":"10.1002\/14651858.CD004136.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004136.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7326\/0003-4819-151-1-200907070-00011","article-title":"Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria","volume":"151","author":"Parfrey","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004136.pub3-BIB0159|cit159","first-page":"e207","article-title":"The relationship between proteinuria and coronary risk: a systematic review and meta-analysis","volume":"5","author":"Perkovic","year":"2008","journal-title":"PLoS Medicine \/ Public Library of Science"},{"issue":"15","key":"10.1002\/14651858.CD004136.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1056\/NEJM199910073411506","article-title":"Nephropathy in patients with type 2 diabetes mellitus","volume":"341","author":"Ritz","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00041552-199703000-00006","article-title":"The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus","volume":"6","author":"Ruggenenti","year":"1997","journal-title":"Current Opinion in Nephrology & Hypertension"},{"issue":"9647","key":"10.1002\/14651858.CD004136.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"Sj\u00f8lie","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD004136.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0197-2456(00)00055-6","article-title":"Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery","volume":"21","author":"Song","year":"2000","journal-title":"Controlled Clinical Trials"},{"issue":"7370","key":"10.1002\/14651858.CD004136.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004136.pub3-BIB0165|cit165","unstructured":"U S Renal Data System USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009 http:\/\/www.usrds.org\/atlas09.aspx"},{"issue":"7440","key":"10.1002\/14651858.CD004136.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","article-title":"British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary","volume":"328","author":"Williams","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD004136.pub3-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004136","article-title":"Antihypertensive agents for preventing diabetic kidney disease. (Protocol)","author":"Strippoli","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD004136.pub3-BIB0168|cit168","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004136.pub2","article-title":"Antihypertensive agents for preventing diabetic kidney disease","author":"Strippoli","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004136.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T12:54:57Z","timestamp":1725454497000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004136.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":168,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004136.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969397.793470660","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717969397.793470484","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,12]]}}}